Thus, considering these clinical data, and the presence of B7-H6 in certain cancers including oral cancers, and its ability to modulate immune cell function that can be exploited in immunotherapeutic approaches, we selected this molecule as a further OSCC biomarker to detect in our system. This evidence concerns the gene NCR3LG1 and lip and oral cavity carcinoma.